Catherine Jorand-Lebrun

USPTO Granted Patents = 23 (Patent Applications = 5)

CIPO Patents = 4

EPO Patents = 11 (Patent Applications = 12)

Average Co-Inventor Count = 4.5

ph-index = 6

Forward Citations = 75(Granted Patents)

Location History:

Boston, MA (US) (2005 - 2008)
Contamine-Sarzin, FR (2006 - 2019)
Billerica, MA (US) (2023 - 2024)

Company Filing History:

Applied Research Systems Ars Holding N.v.

patents

4. 2 out of 40

Laboratoires Serono S.a.

patents

5. 1 out of 10

Laboratories Serono Sa

patents

Years Active: 2005-2024

Loading Chart...

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11873303 - Substituted pyrazoles as type II IRAK inhibitors (2024-01-16),

2. 11702392 - Pyrimidinone derivatives as SHP2 antagonists (2023-07-18),

3. 11696916 - Carboxamide-pyrimidine derivatives as SHP2 antagonists (2023-07-11),

4. 10259795 - Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof (2019-04-16),

5. 10064861 - Macrocyclic pyridazinone derivatives (2018-09-04),

6. 9834528 - Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof (2017-12-05),

7. 9567320 - Pyridazinone-amides derivatives (2017-02-14),

8. 9550794 - Macrocyclic pyridazinone derivatives (2017-01-24),

9. 9447055 - α-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof (2016-09-20),

10. 9073892 - Indazolyl triazol derivatives (2015-07-07),

11. 8415480 - Thiazolidine carboxamide derivatives as modulators of the prostaglandin F receptor (2013-04-09),

12. 8404690 - Piperazine-2-carboxamide derivatives (2013-03-26),

13. 8273769 - Phenoxy acetic acid derivatives (2012-09-25),

14. 8263595 - Triazolopyridine compounds and their use as ask inhibitors (2012-09-11),

15. 8247437 - N-hydroxyamide derivatives and use thereof (2012-08-21),

Title: Catherine Jorand-Lebrun: An Innovator in Pharmaceutical Patents

Introduction

Catherine Jorand-Lebrun is a prominent inventor based in Contamine-Sarzin, France. With an impressive portfolio of 23 patents, she has significantly contributed to the field of pharmaceuticals, particularly in the development of innovative compounds that target various diseases.

Latest Patents

Among her most recent patents, Catherine has focused on the development of substituted pyrazoles as type II IRAK inhibitors. This invention relates to compounds of Formula I and pharmaceutically acceptable compositions that are useful in inhibiting IRAK, a key player in inflammatory pathways. Additionally, she has developed pyrimidinone derivatives as SHP2 antagonists, which are crucial for the treatment of hyperproliferative diseases and disorders in mammals, especially humans. These compounds, including their pharmaceutically acceptable salts, form the basis of her recent innovations for pharmaceutical applications.

Career Highlights

Catherine has worked with notable companies such as Merck Serono S.A. and Merck Patent GmbH, where she honed her skills in drug development and patent creation. Her work has been instrumental in advancing the understanding and treatment of complex health issues, showcasing her commitment to innovation in the pharmaceutical industry.

Collaborations

During her career, Catherine has collaborated with esteemed professionals, including Matthias Schwarz and Dominique Swinnen. These partnerships have enriched her work and expanded the impact of her inventions across the industry.

Conclusion

Catherine Jorand-Lebrun's innovative contributions to pharmacology and her extensive patent portfolio solidify her reputation as a leading inventor in her field. Her work continues to influence the development of new treatments, highlighting the importance of innovation in addressing health challenges.

This text is generated by artificial intelligence and may not be accurate.